Description
LuciBelu 200 MG (Belumosudil) is a first-in-class Rho-associated coiled-coil containing protein kinase 2 inhibitor (ROCK2 inhibitor) an orally bioavailable, small-molecule targeted agent that selectively blocks ROCK2-mediated dysregulation of the Treg/Th17 immune balance and downstream fibrotic signaling that drives chronic graft-versus-host disease (cGvHD) supplied as film-coated tablets, 200 mg strength, in a 30-tablet box and manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos.
Its active ingredient, belumosudil INN, inhibits ROCK2 kinase activity, suppressing STAT3 and IRF4 phosphorylation while simultaneously upregulating STAT5 to restore the regulatory T cell (Treg) to T helper 17 cell (Th17) ratio the fundamental immune imbalance underlying both immune-mediated tissue inflammation and progressive fibrosis in cGvHD. LuciBelu 200 MG is indicated for chronic graft-versus-host disease (cGvHD) after failure of at least 2 prior lines of systemic therapy in adult and pediatric patients aged 12 years and older, administered as a fixed 200 mg once-daily oral dose with food the first and only ROCK2 inhibitor with regulatory approval in this indication.
In the pivotal Phase 2 KD025-213 (ROCKstar) trial in patients with cGvHD after ≥2 prior lines of therapy, belumosudil 200 mg once daily achieved an overall response rate (ORR) of 74% (48/65 evaluable patients), with responses observed across all organ manifestations of cGvHD, a median duration of response of approximately 1.9 years, and 62% of responding patients maintaining their response for at least 1 year. Searching for LuciBelu 200 MG Belumosudil? Mediaid Pharmacy lists this product across its graft-versus-host disease medicines, oncology medicines, and Lucius Pharmaceuticals portfolios and ships it worldwide.
Basic Product Information of LuciBelu 200 MG (Belumosudil)
| Brand Name | LuciBelu 200 MG (Belumosudil) |
| Product Name | LuciBelu |
| Generic Name | Belumosudil INN |
| Drug Class | First-in-Class Rho-Associated Coiled-Coil Containing Protein Kinase 2 Inhibitor (ROCK2 Inhibitor); Chronic Graft-versus-Host Disease (cGvHD) Agent; Treg/Th17 Immunomodulatory Agent; Antifibrotic Targeted Therapy; STAT3/IRF4 Pathway Inhibitor; Targeted Hematology/Oncology Agent |
| Formulation | Film-Coated Tablet (Oral) |
| Available Strength | 200 mg per tablet |
| Available Pack Size | 30 Tablets per Box |
| Dosing | Chronic GvHD (cGvHD): 200 mg orally once daily with food. No dose escalation is used; however, dose reduction to 200 mg every other day is required when co-administered with strong CYP3A4 inducers (such as rifampin or carbamazepine) and in patients with severe renal impairment (eGFR 15–29 mL/min/1.73 m²). Belumosudil should be taken 2 hours before or 2 hours after proton pump inhibitors (PPIs) to avoid reduced absorption. Swallow LuciBelu tablets whole with food. Do not crush or chew. |
| Primary Indication | Chronic graft-versus-host disease (cGvHD) after failure of at least 2 prior lines of systemic therapy in adult and pediatric patients aged 12 years and older, following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Always consult the full prescribing information and the treating hematologist or transplant specialist for complete indication-specific guidance. |
| Manufacturer | Lucius Pharmaceuticals (Lao) Co., Ltd., Laos |
| Country of Origin | Laos |
| Originator Reference Brand | Rezurock® (belumosudil 200 mg tablets, by Kadmon Pharmaceuticals, LLC a Sanofi company approved by the U.S. FDA on July 16, 2021, for cGvHD after failure of ≥2 prior systemic therapy lines). Rezurock® contains belumosudil INN as the active pharmaceutical ingredient in the same ROCK2 inhibitor drug class. LuciBelu is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is supplied through Mediaid Pharmacy for international procurement. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at room temperature (20°C to 25°C); excursions permitted between 15°C and 30°C. Keep in the original packaging and protect from moisture. Keep out of the reach of children. |
How LuciBelu (Belumosudil) Works: First-in-Class ROCK2 Inhibition Restoring Treg/Th17 Balance and Suppressing Fibrosis in Chronic Graft-versus-Host Disease
Belumosudil INN is an orally bioavailable, first-in-class, small-molecule inhibitor of Rho-associated coiled-coil containing protein kinase 2 (ROCK2) a serine/threonine kinase downstream of Rho GTPases that plays a central regulatory role in both immune cell differentiation and pro-fibrotic signaling. Chronic graft-versus-host disease (cGvHD) results from an immunologically dysregulated response in which donor-derived T cells, following allogeneic hematopoietic stem cell transplantation (allo-HSCT), target host tissues in a self-perpetuating cycle of inflammation, immune dysregulation, and progressive fibrosis that can affect the skin, mouth, eyes, lungs, gastrointestinal tract, liver, and musculoskeletal system simultaneously.
At the molecular level, cGvHD is characterized by pathological predominance of T helper 17 cells (Th17) over regulatory T cells (Tregs) an imbalance driven in part by excess ROCK2-mediated STAT3 and IRF4 phosphorylation that promotes Th17 differentiation and Th17-associated proinflammatory cytokine production (including IL-17 and IL-21), while simultaneously suppressing the STAT5-dependent differentiation of FoxP3+ regulatory T cells required to restrain immune-mediated tissue destruction. Belumosudil selectively inhibits ROCK2 kinase activity, blocking STAT3 and IRF4 phosphorylation thereby shifting immune differentiation from a pro-inflammatory Th17-dominant state back toward immune tolerance mediated by FoxP3+ Tregs and simultaneously suppresses ROCK2-driven activation of profibrotic pathways including TGF-β–mediated extracellular matrix deposition and myofibroblast activation that underlies sclerotic cGvHD manifestations.
Pre-clinical characterization demonstrated belumosudil inhibiting ROCK2 with an IC50 of approximately 100 nM, with substantially greater selectivity for ROCK2 over ROCK1 and more than 200 other kinases a selectivity profile that distinguishes belumosudil mechanistically from pan-ROCK inhibitors and from JAK inhibitors, which target an upstream point in the same inflammatory cascade.
The clinical consequence of ROCK2 inhibition in cGvHD is a measurable restoration of Treg/Th17 balance with downstream reductions in pro-inflammatory cytokine release and fibrotic remodeling across affected organs. Unlike immunosuppressants that globally dampen immune function, belumosudil’s targeted ROCK2 inhibition acts at a bifurcation point in immune differentiation simultaneously reducing pathogenic effector T cells while enhancing Treg activity a mechanism that allows organ-level responses across all cGvHD manifestations including high-fibrosis-burden sclerotic disease that is typically refractory to prior therapies.
Pharmacokinetically, belumosudil is absorbed after oral administration and reaches peak plasma concentration (Tmax) in approximately 2 hours; food increases belumosudil exposure (AUC) by approximately 57% relative to fasting, which is why belumosudil must be administered with food. Belumosudil undergoes hepatic metabolism via CYP3A4 as the primary metabolic pathway; co-administration with strong CYP3A4 inducers such as rifampin reduces belumosudil exposure by approximately 85%, necessitating either avoidance of the inducer or dose modification. Proton pump inhibitors (PPIs) reduce belumosudil bioavailability by raising gastric pH patients taking PPIs must separate belumosudil administration from the PPI by at least 2 hours (belumosudil taken 2 hours before the PPI). For the complete range of targeted GvHD and oncology medicines available at Mediaid Pharmacy, visit the graft-versus-host disease medicines collection.
LuciBelu 200 MG (Belumosudil): Indications, Dosing, and Key Safety Information
| Approved Indication | Chronic Graft-versus-Host Disease (cGvHD): LuciBelu (Belumosudil) is indicated for adult and pediatric patients aged 12 years and older with chronic graft-versus-host disease (cGvHD) after failure of at least 2 prior lines of systemic therapy, following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Belumosudil is the first and only ROCK2 inhibitor approved for this indication. |
| Recommended Dose | Chronic GvHD: 200 mg orally once daily with food (1× LuciBelu 200 MG film-coated tablet once daily). Swallow tablets whole with water and a full meal. Administer LuciBelu at the same time each day to maintain consistent plasma exposure. Take LuciBelu at least 2 hours before or 2 hours after any proton pump inhibitor (PPI) dose. |
| Dose Modification | Reduce the LuciBelu dose to 200 mg once every other day in two scenarios: (1) patients with severe renal impairment (eGFR 15–29 mL/min/1.73 m²); and (2) patients receiving a strong CYP3A4 inducer (such as rifampin, carbamazepine, phenytoin, or St. John’s Wort) that reduces belumosudil plasma exposure by approximately 85%. Belumosudil dose modifications for adverse reactions (hematologic or non-hematologic) are managed by dose interruption and resumption under specialist guidance. No dose adjustment is required for mild to moderate hepatic impairment; limited data are available for severe hepatic impairment. |
| Missed Dose | If a LuciBelu dose is missed and it is within 6 hours of the scheduled time, take the missed dose with food as soon as possible. If more than 6 hours have elapsed, skip the missed dose and resume the next dose at the regularly scheduled time. Do not take 2 doses of LuciBelu on the same day to compensate for a missed dose. |
| Key Warnings & Precautions | Serious Infections: Serious and fatal infections including bacterial, fungal, and viral infections have been reported in patients receiving belumosudil. The most common infections in clinical trials included upper respiratory tract infections and pneumonia. Monitor patients for signs and symptoms of infection throughout LuciBelu treatment; institute appropriate anti-infective therapy promptly when infection is confirmed.
Dyspnea and Pulmonary Events: Dyspnea (shortness of breath) was among the most frequently reported adverse reactions (≥20%) in the KD025-213 trial. Monitor patients for new or worsening respiratory symptoms. Evaluate promptly for underlying pulmonary causes, including pneumonia, pleural effusion, or pulmonary cGvHD progression. Embryo-Fetal Toxicity: Belumosudil may cause embryo-fetal harm based on its mechanism of action as a ROCK2 inhibitor ROCK2 signaling plays essential roles in normal fetal development. LuciBelu is not recommended during pregnancy. Females of reproductive potential must use effective contraception during LuciBelu treatment and for at least 1 week after the final dose. Males with female partners of reproductive potential should use effective contraception during LuciBelu treatment and for at least 1 week after the final dose. Breastfeeding is not recommended during LuciBelu treatment and for at least 1 week after the final dose. Drug Interactions CYP3A4 Inducers: Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, enzalutamide, St. John’s Wort) reduce belumosudil exposure by up to 85%; avoid concomitant use or reduce the LuciBelu dose to 200 mg every other day. Proton pump inhibitors reduce belumosudil absorption; separate doses by ≥2 hours. Renal Impairment: Patients with severe renal impairment (eGFR 15–29 mL/min/1.73 m²) require a dose reduction to 200 mg once every other day. Belumosudil is not recommended in end-stage renal disease (eGFR <15 mL/min/1.73 m²) due to insufficient clinical data. |
| Common Adverse Reactions (≥20%) | Infections (including upper respiratory tract infections and pneumonia), asthenia (fatigue/weakness), nausea, diarrhea, dyspnea (shortness of breath), cough, edema (peripheral), hemorrhage, abdominal pain, musculoskeletal pain, and headache. Laboratory abnormalities occurring frequently include decreased phosphate (hypophosphatemia), decreased lymphocytes, increased creatinine, decreased hemoglobin, and increased alanine aminotransferase (ALT). Monitor complete blood counts, renal function, and liver function tests at baseline and periodically throughout LuciBelu treatment. |
| Drug Interactions | Belumosudil is a CYP3A4 substrate and a P-glycoprotein (P-gp) substrate. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, enzalutamide, St. John’s Wort) reduce belumosudil AUC by approximately 85% avoid concomitant use or reduce the LuciBelu dose to 200 mg every other day during co-administration. Proton pump inhibitors (PPIs) (omeprazole, pantoprazole, lansoprazole, esomeprazole) reduce belumosudil AUC by approximately 30% due to increased gastric pH administer LuciBelu at least 2 hours before the PPI dose. Strong CYP3A4 inhibitors may increase belumosudil exposure; no dose adjustment is specified in current labeling, but use with caution and monitor for adverse reactions. Disclose all medications, supplements, and antifungal agents to the treating transplant specialist or hematologist before initiating LuciBelu 200 MG (Belumosudil). |
| Renal Impairment | No dose adjustment is required for mild (eGFR 60–89 mL/min/1.73 m²) or moderate (eGFR 30–59 mL/min/1.73 m²) renal impairment. Patients with severe renal impairment (eGFR 15–29 mL/min/1.73 m²) should receive 200 mg once every other day. LuciBelu is not recommended for patients with end-stage renal disease (eGFR <15 mL/min/1.73 m²). Consult the full prescribing information and the treating nephrologist and transplant hematologist for individualized guidance. |
| Pregnancy & Lactation | Belumosudil may cause embryo-fetal harm based on its mechanism of action as a ROCK2 inhibitor ROCK2 signaling is essential for normal embryonic and fetal development. LuciBelu is not recommended during pregnancy. Females of reproductive potential must use effective contraception during LuciBelu treatment and for at least 1 week after the final dose. Males with female partners of reproductive potential should also use effective contraception during treatment and for 1 week after the final dose. Breastfeeding is not recommended during LuciBelu treatment and for at least 1 week after the final dose. Consult the treating oncologist, hematologist, or transplant specialist before initiating LuciBelu in patients who are pregnant, planning a pregnancy, or breastfeeding. |
Who Should Use LuciBelu 200 MG (Belumosudil)?
LuciBelu 200 MG (Belumosudil) is indicated for a precisely defined patient population: adult and pediatric patients aged 12 years and older with chronic graft-versus-host disease (cGvHD) after failure of at least 2 prior lines of systemic therapy, following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Chronic GvHD represents a major cause of late morbidity and non-relapse mortality after allo-HSCT, affecting up to 50–70% of transplant recipients and characterized by multiorgan immune-mediated and fibrotic damage that progresses despite systemic immunosuppression in a substantial proportion of patients. The 2-prior-therapy threshold defines a heavily pretreated cGvHD population in whom standard corticosteroid-based regimens and second-line agents have been exhausted, creating an urgent need for mechanistically distinct therapies precisely the unmet need belumosudil’s ROCK2-targeted mechanism addresses.
Organ involvement and cGvHD phenotype: In the pivotal KD025-213 (ROCKstar) Phase 2 trial, belumosudil 200 mg once daily demonstrated responses across all assessed cGvHD organ manifestations including skin (the most commonly involved organ), mouth, eyes, gastrointestinal tract, liver, lungs, and musculoskeletal/joint involvement. Critically, belumosudil produced responses in both non-sclerotic (inflammatory) and sclerotic (fibrotic) cGvHD subtypes the latter historically representing the most difficult-to-treat phenotype due to the fibrotic remodeling that is intrinsically resistant to immunosuppressants lacking antifibrotic activity. The ORR of 74% in the 200 mg once-daily cohort, with a median duration of response of approximately 1.9 years and 62% of responders maintaining response for at least 1 year, establishes belumosudil as a durable option in this multiply relapsed/refractory cGvHD setting.
Patient selection considerations: LuciBelu is appropriate for cGvHD patients who have received at least 2 prior systemic therapy lines, which typically include corticosteroids as first-line therapy and one or more second-line agents (such as ruxolitinib, ibrutinib, extracorporeal photopheresis, mycophenolate mofetil, or other immunosuppressants). Patients must not have active uncontrolled infections before initiating LuciBelu. Concomitant immunosuppressants may be continued under specialist supervision; however, strong CYP3A4 inducers commonly used in transplant settings (such as rifampin for antimycobacterial prophylaxis) require LuciBelu dose modification. Patients with severe renal impairment require dose adjustment, as described above. The treating transplant hematologist or oncologist must conduct a thorough benefit-risk assessment including infection status, renal function, concomitant medications, and cGvHD organ involvement before initiating LuciBelu. Transplant centers sourcing LuciBelu alongside complementary agents for post-transplant GvHD management can browse the Mediaid Pharmacy chronic GvHD treatment medicines and oncology medicines portfolios for the full selection available for international delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for LuciBelu 200 MG (Belumosudil)
Mediaid Pharmacy is a Dhaka-based supplier of specialty oncology and targeted hematology medicines with worldwide shipping to patients, transplant centers, cancer hospitals, bone marrow transplant programs, and international distributors across all regions. LuciBelu 200 MG (Belumosudil), manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is supplied as film-coated tablets 200 mg per tablet, 30 tablets per box with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order. The 30-tablet monthly pack aligns precisely with the once-daily dosing schedule of belumosudil (200 mg once daily), providing transplant pharmacies, hematology centers, and individual patients with a single-box monthly supply that simplifies inventory and dispensing.
Hematology-oncology centers treating post-transplant cGvHD patients; hospital formulary teams at bone marrow transplant programs; international distributors; and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding LuciBelu Belumosudil stock availability, current pricing, and international delivery timelines. Procurement teams co-sourcing LuciBelu with other targeted hematology or GvHD management agents can browse the complete Mediaid Pharmacy oncology medicines collection and the Lucius Pharmaceuticals medicines portfolio before requesting a consolidated quotation.
Why Choose LuciBelu 200 MG (Belumosudil) from Mediaid Pharmacy?
LuciBelu 200 MG (Belumosudil) provides transplant hematologists, oncologists, and bone marrow transplant specialists with a first-in-class, mechanistically distinct ROCK2 inhibitor that addresses a critical unmet need in multiply pretreated chronic graft-versus-host disease a patient population with limited approved options and historically poor outcomes on salvage regimens. Belumosudil’s approval rests on the KD025-213 (ROCKstar) Phase 2 trial, in which 200 mg once daily achieved an overall response rate of 74% in patients with cGvHD after ≥2 prior systemic therapy lines, with a median duration of response of approximately 1.9 years a durability outcome that is clinically significant in a patient group with high symptom burden and risk of irreversible organ damage from uncontrolled cGvHD. Responses were observed across all organ manifestations, including sclerotic skin, fasciitis, and pulmonary cGvHD the high-fibrosis-burden manifestations most refractory to conventional immunosuppression reflecting belumosudil’s dual activity as both an immunomodulator (restoring Treg/Th17 balance) and an antifibrotic agent (suppressing ROCK2-dependent TGF-β/myofibroblast activation).
The simple once-daily oral dosing of LuciBelu a fixed 200 mg once daily with food, with no platelet-count-dependent dose stratification or complex titration schedules simplifies treatment implementation for both the patient and the prescribing transplant hematologist, reducing adherence barriers in a patient population that already carries a high burden of polypharmacy from immunosuppressant regimens. The 30-tablet-per-box pack format of LuciBelu directly corresponds to a standard 30-day monthly treatment supply, streamlining pharmacy dispensing and procurement planning for transplant programs on a monthly ordering cycle. LuciBelu is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is available through Mediaid Pharmacy with full product documentation, specialist supply coordination, and worldwide shipping from Dhaka. To source additional Lucius Pharmaceuticals oncology and hematology medicines, visit the Mediaid Pharmacy Lucius Pharmaceuticals medicines section and the graft-versus-host disease medicines portfolio, and contact the team for a personalized quotation.
Frequently Asked Questions About LuciBelu 200 MG (Belumosudil)
What is LuciBelu 200 MG (Belumosudil) used for?
LuciBelu 200 MG (Belumosudil) is a first-in-class ROCK2 inhibitor used for chronic graft-versus-host disease (cGvHD) after failure of at least 2 prior lines of systemic therapy in adult and pediatric patients aged 12 years and older following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Belumosudil selectively inhibits ROCK2 kinase to restore the regulatory T cell (Treg) to T helper 17 cell (Th17) immune balance, simultaneously suppressing ROCK2-mediated profibrotic signaling that drives sclerotic cGvHD organ damage. LuciBelu is the only approved ROCK2 inhibitor for this indication. The originator brand for belumosudil is Rezurock® (Kadmon Pharmaceuticals/Sanofi), approved by the U.S. FDA on July 16, 2021. LuciBelu, manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is available through Mediaid Pharmacy with worldwide shipping.
What is the generic name of LuciBelu?
The generic name of LuciBelu is belumosudil INN. LuciBelu is the brand name registered by Lucius Pharmaceuticals (Lao) Co., Ltd. for belumosudil manufactured in Laos. LuciBelu is formulated as film-coated tablets in a single strength of 200 mg, supplied in a 30-tablet box corresponding to a standard 30-day monthly treatment supply at the approved once-daily dose. The originator reference brand is Rezurock® (Kadmon Pharmaceuticals, a Sanofi company). Mediaid Pharmacy distributes LuciBelu globally with worldwide shipping to patients, transplant centers, cancer hospitals, and specialist clinics.
What is the difference between LuciBelu (Belumosudil) and Rezurock (Belumosudil)?
LuciBelu and Rezurock® both contain belumosudil INN as the active pharmaceutical ingredient and share the same ROCK2 inhibitor mechanism of action, the same approved indication (cGvHD after ≥2 prior systemic therapy lines), and the same 200 mg once-daily oral dosing schedule. Rezurock® is the originator brand developed by Kadmon Pharmaceuticals, LLC (a Sanofi company), approved by the U.S. FDA on July 16, 2021, and marketed primarily in the United States. LuciBelu is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is available through Mediaid Pharmacy for international procurement by transplant centers and patients in regions where Rezurock® may be unavailable or cost-prohibitive. For the full range of graft-versus-host disease treatment medicines at Mediaid Pharmacy, explore the complete GvHD medicines collection.
How is LuciBelu 200 MG (Belumosudil) administered?
LuciBelu (Belumosudil) is administered orally once daily at a fixed dose of 200 mg with food. Food increases belumosudil bioavailability by approximately 57%; therefore, LuciBelu must always be taken with a meal not in a fasted state. Swallow LuciBelu film-coated tablets whole with water; do not crush, split, or chew the tablets. If a proton pump inhibitor (PPI) is also prescribed, take LuciBelu at least 2 hours before the PPI dose to avoid PPI-related reduction in belumosudil absorption. Take LuciBelu at the same time each day to maintain consistent plasma levels. If a dose is missed within 6 hours of the scheduled time, take it with food as soon as possible; if more than 6 hours have passed, skip the missed dose and resume the next scheduled dose. Do not double doses. If strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s Wort) are co-administered, reduce the LuciBelu dose to 200 mg once every other day under hematologist guidance.
What are the side effects of LuciBelu 200 MG (Belumosudil)?
The most common adverse reactions of belumosudil occurring in 20% or more of patients in the KD025-213 Phase 2 trial include infections (particularly upper respiratory tract infections and pneumonia), asthenia (fatigue and weakness), nausea, diarrhea, dyspnea (shortness of breath), cough, peripheral edema, hemorrhage (including bruising and epistaxis), abdominal pain, musculoskeletal pain, and headache. Laboratory abnormalities reported with belumosudil include decreased phosphate (hypophosphatemia), decreased lymphocyte count, increased serum creatinine, decreased hemoglobin, and elevated liver enzymes (ALT). Serious infections including bacterial, fungal, and viral infections have been reported; monitor patients actively throughout LuciBelu treatment and initiate appropriate anti-infective therapy without delay. Dyspnea requires prompt evaluation for pulmonary infection, pleural effusion, or pulmonary cGvHD. Always discuss the complete safety profile, individual risk factors, and management strategies with the treating transplant hematologist before and throughout LuciBelu treatment.
How effective is Belumosudil (LuciBelu) for chronic graft-versus-host disease?
Belumosudil has demonstrated clinically meaningful efficacy in the pivotal KD025-213 (ROCKstar) Phase 2 trial in patients with cGvHD after failure of at least 2 prior systemic therapy lines. In the 200 mg once-daily dose cohort (65 evaluable patients), belumosudil achieved an overall response rate (ORR) of 74% (48/65 patients), with responses observed across all organ manifestations of cGvHD, including both inflammatory and sclerotic phenotypes. The median duration of response was approximately 1.9 years (22.7 months), with 62% of responding patients maintaining their response for at least 1 year establishing the durability of belumosudil’s clinical benefit in this multiply pretreated population. Responses were seen regardless of cGvHD severity, number of organs involved, or prior therapy type (including patients who had previously received ruxolitinib or ibrutinib as prior lines). LuciBelu delivers the same active ingredient belumosudil INN at the same approved dose, sourced through Mediaid Pharmacy with worldwide shipping. For the complete oncology medicines range at Mediaid Pharmacy, visit the oncology medicines collection.
Is LuciBelu 200 MG (Belumosudil) safe during pregnancy or while breastfeeding?
No. Belumosudil may cause embryo-fetal harm based on its mechanism of action as a ROCK2 inhibitor ROCK2 signaling plays essential roles in normal embryonic and fetal development, making ROCK2 inhibition during pregnancy a risk for serious developmental toxicity. LuciBelu is not recommended during pregnancy. Females of reproductive potential must use effective contraception during LuciBelu treatment and for at least 1 week after the final dose. Males with female partners of reproductive potential should use effective contraception during LuciBelu treatment and for at least 1 week after the final dose. Breastfeeding is not recommended during LuciBelu treatment and for at least 1 week after the final dose. If pregnancy occurs during belumosudil treatment, the treating transplant hematologist or oncologist should be notified immediately. Consult the treating specialist before starting LuciBelu if pregnant, planning a pregnancy, or breastfeeding.
Can I order LuciBelu 200 MG (Belumosudil) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies LuciBelu 200 MG (Belumosudil) to patients, transplant hematology centers, cancer hospitals, bone marrow transplant programs, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order LuciBelu 200 MG (Belumosudil) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.